PipelineReview.com14h
ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
NORTH CHICAGO, IL, USA I March 15, 2025 I AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the ...
PipelineReview.com14h
iOncologi, Inc. Acquires TargImmune Therapeutics to Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors
GAINESVILLE, FL, USA I March 14, 2025 I iOncologi, Inc., a clinical-stage biopharmaceutical company focused on advancing immunotherapy platform technologies, ...
PipelineReview.com14h
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or ...
PipelineReview.com14h
Sanofi adopts FDA-selected flu strains to ensure readiness for the 2025-26 flu season
BRIDGEWATER, NJ, USA I March 14, 2025 I Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug ...
PipelineReview.com14h
Skyhawk Therapeutics Presents at Huntington’s Disease Youth Organization HDYO International Congress 2025
Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease to members of the Huntington's Disease Youth ...
PipelineReview.com2d
China’s First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease
SAN FRANCISCO, CA, USA and SUZHOU, China I March 14, 2025 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company ...
PipelineReview.com2d
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
PLYMOUTH MEETING, PA, USA I March 13, 2025 I INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help ...
PipelineReview.com2d
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues ...
PipelineReview.com3d
SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
BARCELONA, Spain I March 13, 2025 I SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations ...
PipelineReview.com3d
EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs)
EnnoDC presents positive Phase I data at CROI 2025, demonstrating long-lasting immunity induced by Antibody Mediated Vaccines (AMVs) ...
PipelineReview.com3d
SOTIO Expands ADC Pipeline and Synaffix Collaboration to Develop Two Novel Bispecific Candidates, SOT112 and SOT113
Three-program alliance with Synaffix reflects SOTIO’s commitment to further broaden and advance innovative ADC pipeline ...
PipelineReview.com3d
STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
JERSEY CITY, NJ, USA I March 12, 2025 I Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® ...